Exact Mass: 365.0475

Exact Mass Matches: 365.0475

Found 25 metabolites which its exact mass value is equals to given mass value 365.0475, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Fludarabine

{[(2R,3S,4S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

C10H13FN5O7P (365.0537)


Fludarabine is only found in individuals that have used or taken this drug. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

   

Fludara

{[5-(6-amino-2-fluoro-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid

C10H13FN5O7P (365.0537)


D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents

   

2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid

2-hydroxy-4-{2-[(4-methylbenzenesulfonyl)oxy]acetamido}benzoic acid

C16H15NO7S (365.0569)


   

Luxabendazole

N-{6-[(4-fluorobenzenesulphonyl)oxy]-1H-1,3-benzodiazol-2-yl}methoxycarboximidic acid

C15H12FN3O5S (365.0482)


   
   

Maybridge3_003568

Maybridge3_003568

C16H15NO5S2 (365.0392)


   

Fludarabine phosphate

Fludarabine phosphate

C10H13FN5O7P (365.0537)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

   

Naphthaloximidodiethyl thiophosphate

Naphthaloximidodiethyl thiophosphate

C16H16NO5PS (365.0487)


   

1-(4-bromo-2-phenylmethoxyphenyl)-N-phenylmethanimine

1-(4-bromo-2-phenylmethoxyphenyl)-N-phenylmethanimine

C20H16BrNO (365.0415)


   

Pyrido[1,2-a]benzimidazole, 1,2,3,4-tetrahydro- (6CI,7CI,8CI,9CI)

Pyrido[1,2-a]benzimidazole, 1,2,3,4-tetrahydro- (6CI,7CI,8CI,9CI)

C18H11N3O4S (365.047)


   

Luxabendazole

Luxalbendazole

C15H12FN3O5S (365.0482)


C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent

   

1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxy]-, phenylmethyl ester

1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxy]-, phenylmethyl ester

C14H14F3NO5S (365.0545)


   

(2,3,4,5,6-pentafluorophenyl) 6-phenylpyridine-3-carboxylate

(2,3,4,5,6-pentafluorophenyl) 6-phenylpyridine-3-carboxylate

C18H8F5NO2 (365.0475)


   
   

2-(2-Hydroxy-4-benzoyloxyphenyl)-5-chlorobenzotriazole

2-(2-Hydroxy-4-benzoyloxyphenyl)-5-chlorobenzotriazole

C19H12ClN3O3 (365.0567)


   

O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-acetyloxyiminoacetate

O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-acetyloxyiminoacetate

C11H16N3O7PS (365.0447)


   

Foslinanib

Foslinanib

C16H13FNO6P (365.0464)


C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor

   

Leteprinim potassium

Leteprinim potassium

C15H12KN5O4 (365.0526)


C26170 - Protective Agent > C1509 - Neuroprotective Agent

   

5-Monophosphate-9-beta-D-ribofuranosyl xanthine

5-Monophosphate-9-beta-D-ribofuranosyl xanthine

C10H14N4O9P+ (365.0498)


   

4-Cyanobenzoic acid [4-oxo-6-[(2-pyrimidinylthio)methyl]-3-pyranyl] ester

4-Cyanobenzoic acid [4-oxo-6-[(2-pyrimidinylthio)methyl]-3-pyranyl] ester

C18H11N3O4S (365.047)


   

N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2-difluoroacetamide

N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2-difluoroacetamide

C16H13F2N3OS2 (365.0468)


   

5-(2,5-dichlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide

5-(2,5-dichlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide

C15H13Cl2N5O2 (365.0446)


   

ethyl 2-{[(1E)-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)methylene]amino}-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate

ethyl 2-{[(1E)-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)methylene]amino}-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate

C15H15N3O4S2 (365.0504)


   

S3I-201

2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid

C16H15NO7S (365.0569)


   

HIF-2α-IN-2

HIF-2α-IN-2

C17H13F2NO4S (365.0533)


HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA)[1].